Genmab A/S, of Copenhagen, Denmark, won a supplemental biologics license application for the use of ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).